A group of 21 doctors from the US and Canada has published a...
- US doctors propose universal health care to fix ‘dysfunctional’ system
- US Health Secretary proposes changes to Medicare plans
- Trump’s drug price plans: a ‘sugar-coated nothing pill’?
- Biotech M&A: will the 2018 surge last?
- AbbVie’s risankizumab edges closer to approval for moderate-to-severe psoriasis
UK BEIS report calls for pharmaceutical post-Brexit deal
A report by the UK Business, Energy and Industrial Strategy Committee (BEIS) has stressed the need for a post-Brexit deal for the pharmaceutical industry to avoid harming patients and maintain current footprint in the sector.
US doctors propose universal health care to fix ‘dysfunctional’ system
A group of 21 doctors from the US and Canada has published a proposal aimed at ensuring access to ‘safe, innovative, and affordable’ medications.
US Health Secretary proposes changes to Medicare plans
US Health and Human Services secretary Alex Azar has announced changes to Medicare Part B in a bid to lower drug prices.
Trump’s drug price plans: a ‘sugar-coated nothing pill’?
In a long-awaited speech delivered at the White House Rose Garden on Friday, Trump launched what he described as ‘the most sweeping action in history to lower the price of prescription drugs for the American people’. However, with big pharma left relatively unscathed, will the proposals have any real impact on drug pricing?
Biotech M&A: will the 2018 surge last?
Analysts are predicting a surge of M&A activity in the biotech space, with large pharma firms looking to pad their pipelines with new acquisitions, US tax reform freeing up cash flow, and rapidly-consolidating US healthcare buyers likely to put more pressure on the price of existing drugs. How is the biotech M&A landscape likely to develop over the course of 2018?
US President Trump unveils plan to lower drug prices
US President Donald Trump has outlined a plan to cut down the price of prescription drugs in the country during his speech at the White House Rose Garden.
AbbVie’s risankizumab edges closer to approval for moderate-to-severe psoriasis
AbbVie has submitted a marketing authorization application (MAA) for risankizumab, an interleukin 23 (IL-23) inhibitor, to the European Medicines Agency (EMA) with the intention of seeking approval for its use in moderate-to-severe plaque psoriasis.
FDA seeks to shut down unauthorised stem cell clinics
The US Food and Drugs Administration (FDA) is seeking permanent injunctions to stop two stem cell clinics in California and Florida from marketing stem cell products without FDA approval after reports of patients being made blind.
Roundtable: experts share their views on clinical trial transparency
The accessibility of clinical trial data is an issue which divides opinion in the pharmaceutical industry. Nine experts offer their views on the importance of transparency and what can be done to improve it.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.